External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ETA 2022

-
Coming soon
10:00 AM
Duration 12mins Studio
Entrectinibâ–¼ in patients with NTRK fusion-positive (NTRK-fp) thyroid cancer: updated data from STARTRK-2
Bowles D, Bazhenova L, Hescot S, Folprecht G, Daga H, Massarelli E, Conley A, Lamartina L, Lin J, Ahn E, Osborne S, Heinzmann S, Carrizosa D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar